Related Experiment Video
Updated: Sep 28, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Clinical Presentation of Hepatocellular Carcinoma in African Americans vs. Caucasians: A Retrospective Analysis
Hrishikesh Samant1, Kapil Kohli1, Krunal Patel2
1Section of Gastroenterology and Hepatology, Departments of Medicine, Ochsner-LSU Health Sciences Center in Shreveport, Shreveport, LA 71103, USA.
Insights
African American patients with hepatocellular carcinoma (HCC) were diagnosed at an older age and had more risk factors than white patients. These findings highlight disparities and inform targeted HCC surveillance programs.
Area of Science:
- Hepatology
- Oncology
- Public Health
Background:
- Hepatocellular carcinoma (HCC) is a significant cause of cancer mortality globally.
- Ethnic disparities in HCC survival exist, but contributing factors require further understanding.
- A tertiary medical center with a majority African American population was studied to explore HCC survival factors.
Purpose of the Study:
- To investigate the influence of risk factors, including ethnic background, on hepatocellular carcinoma (HCC) survival.
- To identify demographic, comorbidity, and tumor-related differences in HCC patients across ethnic groups.
Main Methods:
- Retrospective analysis of 229 HCC patient data from 2008-2018.
- Inclusion of demographics, comorbidities, liver disease, and tumor characteristics.
- Statistical analysis using Chi-Square and one-way ANOVA.
Main Results:
- African American (AA) HCC patients (57.2%) were older at diagnosis compared to non-Hispanic Caucasians (42.7%).
- AA patients exhibited higher rates of diabetes, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
- AA patients presented with larger HCC tumors and were more likely to be outside Milan criteria.
Conclusions:
- AA patients with HCC face unique challenges, including older age at diagnosis and increased metabolic risk factors.
- Findings suggest a need for tailored HCC surveillance strategies to address ethnic disparities.
- Understanding these factors is crucial for improving prognostic and diagnostic approaches in HCC care.
Abstract:
Hepatocellular carcinoma (HCC) remains an important form of cancer-related morbidity and mortality in the U.S. and worldwide. Previous U.S.-based studies on survival suggest ethnic disparities in HCC patients, but the complex interplay of multiple factors that contribute are still incompletely understood. Here we considered the influences of risk factors contributing towards HCC survival, including ethnic background, over ten years at a premier academic medical center with a majority (57.20%) African American (AA) population. Retrospective HCC data were collected from 2008-2018 at LSUHSC-Shreveport, an urban tertiary medical center. Data included demographics, comorbidities, liver disease characteristics, and tumor parameters. Statistical analysis was performed using Chi Square and one-way ANOVA. Results: 229 HCC patients were identified (male 78.6%). The mean HCC age at diagnosis was 61 years (SD = 7.3). Compared to non-Hispanic Caucasians (42.7%), AA patients (57.2% of total) were older at presentation, had more frequent diabetes/dyslipidemia/NAFLD (45 (34.3%) compared with 19 (19.3%) in non-Hispanic Caucasians, p = 0.02), and had a larger HCC burden at diagnosis. We conclude that compared to white patients, despite having similar BMI and MELD scores and rates of portal vein thrombosis, AA patients with HCC in our cohort were older at presentation, had a significantly increased incidence of modifiable metabolic risk factors including diabetes, higher AFP values, increased incidence of gallstones, and larger sized HCCs, and were more likely to be outside Milan criteria. These findings have important prognostic and diagnostic implications for developing a more targeted HCC surveillance program.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
10:35Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013